Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeNON PROFITTidepool Completes Its Summative Human Factors Validation Stud for Tidepool Loop: Open...

Tidepool Completes Its Summative Human Factors Validation Stud for Tidepool Loop: Open Source Diabetes Nonprofit Down to Final Steps in Preparation for FDA Submission

November 12, 2020

Tidepool, a 501(c)3 nonprofit committed to providing free software for the diabetes community, today announced the completion of its summative human factors validation study for Tidepool Loop, an automated insulin dosing app in development intended for the management of Type 1 diabetes.

Tidepool notes: Built on the extraordinary foundation of the do-it-yourself diabetes community’s original Loop app, Tidepool Loop is a first-of-its-kind project to take a patient-led innovation and shepherd it through US FDA’s regulatory process with the goal to make the app more broadly accessible to people with diabetes and their clinicians. Tidepool is partnered with device makers Insulet (PODD), Dexcom (DXCM), Medtronic (MDT), and two additional yet-to-be-named medical device companies for future inclusion of their components with the Tidepool Loop platform in development.

Tidepool’s validation study, announced on the company’s blog in September, included over 50 participants. Cohorts included adults with type 1 diabetes, caregivers of people with type 1 diabetes, independent pediatric participants with type 1 diabetes, and pediatric participants with type 1 diabetes paired with their caregivers. Each participated in the remote study using Apple iPhones and Apple Watches preloaded with software by Tidepool. Participants simulated completion of certain critical tasks related to the delivery of insulin, configuration of settings, and the entry of data via the app’s user interface. Tidepool was supported in the study conduct by Core Human Factors, Inc in Pennsylvania, with remote conduct of the Tidepool study arms made possible through remote user research software by Lookback.

The final report from the study will be included with Tidepool’s upcoming medical device submission to US FDA. All submission documents will be published and available at tidepool.org.

The human factors study comes on the heels of a broader Loop Observational Study conducted by JAEB Center for Health Research that studied the algorithm as it’s employed in the Loop mobile application developed in the do-it-yourself diabetes community. Tidepool has implemented this algorithm in Tidepool Loop and will submit study data from the Loop Observational Study in support of its submission.

“I could not be prouder of our team and how we quickly adapted to the challenges of conducting a remote study during a pandemic,” said Howard Look, CEO and co-founder of Tidepool. “Our next step is to submit Tidepool Loop for review to FDA in the hopes of seeing our software cleared and available in the App Store. We couldn’t do this work without the community — who stepped up to volunteer for the study and who continue to support our mission through our Pave It Forward fundraising campaign.”

Tidepool Loop was initially supported by grants from JDRF and The Leona M. and Harry B. Helmsley Charitable Trust, and further supported by donations from a diverse community of individual funders impacted by their experience with diabetes. Tidepool recently initiated the #PaveItForward community fundraising campaign to give people with diabetes the opportunity to support the Tidepool Loop development effort.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy